On November 4, 2025, ATAI Life Sciences N.V. held a meeting where shareholders approved the acquisition of Beckley Psytech and the redomiciliation to Delaware, with 121 million votes in favor of the acquisition out of about 156 million shares represented. The changes include appointing two new directors and adjusting the company's articles of association to support the merger and share class modifications. This is a significant event for the company.